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Histopathological grading and DNA ploidy as prognostic markers in
metastatic prostatic cancer
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Sinary The present study compares the prognostic potential of tumour grade and DNA ploidy status in
patients with advanced-stage prostatic cancer. Two outcome groups were selected on the basis of time to
progression and survival after orchiectomy. A poor-outcome group consisted of 32 therapy-resistant patients
who experienced disease progression during the first year after orchiectomy and subsequently death due to
prostatic cancer during the following year. A good-outcome group consisted of 27 therapy-responsive patients
who showed disease regression and no signs of progression during a 3 year follow-up. The primary tumours
were graded twice according to WHO and Gleason classifiction systems by two pathologists. Final agreement
between the pathologists was obtained after a consensus meeting. The analysis revealed no prognostic
importance of the two histological classification systems (P = 0.62 and P = 0.70) and disclosed weak inter- and
intra-observer reproducibility (Ic<0.70). DNA ploidy analyses were performed by image cytometry on
formalin-fixed, paraffn-embedded samples of the primary tumours. Overall, 48% of the tumours were diploid,
20% tetraploid and 32% anueploid. DNA ploidy status did not discriminate between the two outcome groups
(P = 0.46). Histological grade and DNA ploidy showed no prognostic importance in patients with prostatic
cancer and skeletal metastases.
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Metastatic prostatic cancer is an aggressive and incurable
disease. At the time of diagnosis, about 75% of the patients
have either locally advanced or disseminated disease. The
skeleton is the primary site of metastases in 85% of the
patients who die of prostate cancer (Jacobs, 1983). So far,
androgen deprivation is the only palliative treatment that
gives symptomatic relief and disease regression, which are
achieved in about 70% of the patients with metastatic
disease. Disease regression is, however, not permanent, and
after a while the tumour cells escape the influence of andro-
gen suppression. The mean progression-free interval is 12-18
months and the mean survival is 24-36 months after the
initiation of hormonal therapy, depending on the tumour
cells' sensitivity to endocrine manipulation (Ernst et al., 1991;
Mahler and Denis, 1992). Histopathological grade, serum
tumour markers and performance status are the parameters
most used to predict the outcome for the individual patient
with metastatic disease. However, no presently available
parameter can distinguish patients with a favourable response
from those with poor response to androgen withdrawal.
The two common histological grading systems for prostate
carcinomas are the Gleason (1977) system and the WHO
classification system (Mostofi et al., 1980). Both are subjec-
tive methods with large variations in inter- and intra-observer
reproducibility (Mostofi, 1976; Swanholm et al., 1990;
Gleason, 1992).
More objective methods that can afford greater accuracy in
assessing the relative risk of progression and death from
cancer diseases have been sought. Ploidy analysis of solid
tumours has revealed a high aneuploidy rate in poorly differ-
entiated tumours, and survival appears to be adversely affect-
ed by increasing DNA index (Merkel and McGuire, 1990;
Williams and Daly, 1990). Ploidy has also been suggested to
be an important prognostic factor (Lee et al., 1988; Peters et
al., 1990; Miller et al., 1991; Zetteberg and Forsslund, 1991;
Forsslund et al., 1992). Increasing frequency of DNA aneu-
ploidy has been demonstrated with advanced stage and loss
of tumour differentiation (Frankfurt et al., 1985). On the
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other hand, there are reports stating a limited prognostic
value of nuclear DNA content, especially in advanced-stage
cancer (White et al., 1990; Adolfsson and Tribukait, 1991;
Hedlund et al., 1991).
The aims of the present study were to investigate both the
prognostic value of the histological grade according to WHO
and Gleason classification systems and the prognostic value
of DNA ploidy in the presence of skeletal metastases. Addi-
tionally, a statistical evaluation of inter- and intra-observer
reproducibility of the two grading systems was performed.
Patent and methods
Patients
The Scandinavian Prostatic Cancer Group Study no.2
(SPCG-2) investigated the concept of total androgen block-
ade for metastatic prostatic cancer. This study found no
advantage in adding cyproterone acetate (CPA) 150 mg daily
to orchiectomy compared with the standard treatment orchi-
ectomy (J0rgensen et al., 1993). The present investigation is
based on two outcome groups of patients, selected from the
SPCG-2 study according to their time to progression and
time to cancer-related death. All patients had histologically
confirmed prostatic carcinoma and skeletal metastases (M1)
diagnosed by bone scans or radiographs. None of the
patients had any previous prostatic cancer therapy before
biopsy of the tumour. The patients were followed with
repeated clinical examinations according to the protocol
either to progression or to death during a follow-up period of
3 years after hormonal treatment. The first group consisted
of patients showing disease progression during the first year
and death due to cancer progression during the subsequent
year. This poor-prognosis group was classified as therapy
resistant. The second group comprised patients with tumour
regression and no signs of progression during a 3 year
follow-up. This group was classified as therapy responsive
with good prognosis. In the poor-prognosis group, 32
patients had sufficient specimens for histological grading and
image cytometry analysis (ICM) from the primary tumour,
obtained at entry to the trial. Twenty-eight specimens were
obtained by transurethral resection (TUR) and four by Tru-
cut biopsy (TC). In the good-prognosis group, 27 patientsPioposiemarkrsi -dMs irprostiancer
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had sufficient material: 23 by TUR, two by TC and two by
open prostatectomy. The average age at diagnosis of the
patients included in the poor-prognosis group was 71.4 years
(56-85 years). In the good-prognosis group the average age
was 73.3 years (60-85 years).
four or more nuclei exceeded the 5c value without cells in the
8c area or if a prominent peak was identified between 2c and
4c (Figures 3 and 4). Histograms with one, two or three
nuclei exceeding Sc were classified as euploid (Figure 5)
(Berner et al., 1993).
Histological evaluation
All haematoxylin and eosin-stained slides (3-9 per patient)
from the primary tumours, sampled before start of treatment,
were reviewed by a senior pathologist. The presumptive most
representative slide from each tumour was selected and grad-
ed in two different sessions according to both Gleason and
WHO classification systems, without knowledge of the
clinical data or previous histological grade. The same slides
were independently reviewed in the same manner by another
senior pathologist. Consensus was obtained at a meeting in
which the two pathologists reviewed all the slides together.
Image c)ytometrv analysis (ICM)
The carcinomatous areas were outlined on paraffin blocks
corresponding to the selected slide and used for ICM. From
each selected block one or two 50.pm sections were cut.
After deparaffinisation with xylol, the tissues were rehydrated
in graded ethanol, rinsed in phosphate-buffered saline (PBS,
pH 7.4), and incubated with protease (Sigma no. 24) at 37C
for 60 min. During this period a Pasteur pipette was used for
mechanical disintegration. The protease activity was stopped
by adding 4 ml of cold PBS, and thereafter the specimens
were rinsed twice in 4 ml of PBS. The suspension was filtered
through a 100pim nylon filter and the cell density was cal-
culated with a Burker chamber before centrifugation in a
cytospin centrifuge (Hettich, Tuttlingen, Germany) on polyly-
sine-coated slides at 1250 g. The isolated cells were post-fixed
in 4% formalin for at least 12 h at room temperature.
A hydrolysis curve was made at Omin intervals up to
180 min with 5 N hydrochloric acid at 22C, followed by 2 h
staining with basic fuchsin. The plateau of the curve was
found to be at 60 min. The slides were studied using a Zeiss
Axiotron microscope using plan-Neofluar 40 x /0.75 with a
546nm green filter. Images were digitised using a charge-
coupled device (CCD) camera (Hamamatsu C3077) and
transferred to the IBAS image processing unit (Kontron,
Germany) at a final magnification of 1400 x and a resolution
of 254 nm per pixel. The ploidy analysis consisted of
semiautomatic measurements ofapproximately 350 nuclei per
specimen including 25-50 lymphocytes (serving as internal
quality control).
From each image, only intact, well-prepared nuclei were
selected, and used to measure morphometric and densito-
metric features. The analyses were done by measuring inte-
grated optical density (IOD) after shading correction of each
input image which consisted of 512 x 512 x 8 bits. All images
were selected at random. For each image, all complete, well-
preserved nuclei were measured.
The inter- and intra-observer reproducibility of the
measurements were recorded in five randomly selected slides,
and the histogram classification was well agreed upon within
all five cases. The software used for measurements and ana-
lysis, was developed by us, using C-library from Kontron
Bildanalyse, Munich, Germany.
Classification ofDNA histograms
A specimen was classified as diploid (2c) if only one peak
[coefficient of variation (CV) 4-15%, mean 8%] was present
to the right of the diploid control cells. The relative distance
between the control cells and the defined diploid peak was
found to be 1.6 ± 0.23 (Figure 1). This diploid peak (2c) was
used for calculation of the ploidy of the other peaks and the
CV. A specimen was considered to be in the tetraploid range
when more than 10% of the analysed nuclei were found in
the tetraploid region (2 x 2c ± 2 x CV) (Figure 2). A speci-
men was classified as aneuploid either if the DNA content of
Statistical analysis
To test the dependence of the response values on the various
variables, i.e. histological grading and ploidy, 2 x M con-
tingency and x2 tests were performed. The results were check-
ed by Spearman rank correlation tests. Also, interdependence
between variables, i.e. grading vs ploidy, was examined in
this manner.
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The Gleason scores were rearranged in three main levels
for statistical analysis: Level 1 = Gleason score 2-4. Level
2=Gleason score 5-7. Level 3=Gleason score 8-10. The
WHO grading system is: grade 1 = well differentiated; grade
2= moderately differentiated; grade 3 = poorly differen-
tiated.
The inter- and intra-observer agreement of histological
grading obtained with WHO and Gleason classification
system was calculated by K-statistics and the computer soft-
ware program 'Agree' was used (Swanholm et al., 1989). The
K-coefficient reveals whether the reproducibility of a diagnos-
tic test exceeds that obtained by chance alone (Landis and
Kock, 1977; Silcocks, 1983): K= 1 means full agreement and
K =0 is found when the agreement may solely be explained
by chance; K<0 is found when the observed agreement is less
than expected by chance; K >0.70 indicates a high degree of
concordance. The Spearman rank correlation test and con-
tingency test were used to calculate correlation between
histological grading and ploidy.
Results
The results of histological grading obtained after consensus
are listed in Table I. According to the WHO classification
system, 11.9% of the tumours were well differentiated, 32.2%
were moderately differentiated and 55.9% were poorly differ-
entiated. According to the Gleason classification system,
15.3% of the tumours had a Gleason score of 2-4, 69.5%
Gleason score 5-7 and 15.3% Gleason score 8-10. There
was no significant difference between the two outcome
groups ofpatients with regard to the WHO (P = 0.67) or the
Gleason (P = 0.50) classification systems. Eight per cent of
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the tumours in the therapy-sensitive group were well
differentiated, compared with 16% in the therapy-resistant
group. Furthermore, in the therapy-sensitive group 33% of
the tumours were moderately and 59% were poorly
differentiated compared with 31% and 53%, respectively, in
the therapy-resistant group. Eleven per cent achieved
Gleason score 2-4 in the therapy-sensitive group compared
with 19% in the therapy-resistant group. Sixty-nine per cent
of the patients have Gleason score 5-7. Seventy-four per
cent of these were in the therapy-sensitive group, compared
with 66% in the therapy-resistant group. The tumours with
Gleason scores of 8-10 were equally distributed in the two
groups. Thus, neither the Gleason system nor the WHO
system discriminated between the two groups of patients.
The overall agreement, the agreement by chance, and the
K-values for the two pathologists are given in Table II with
regard to both intra- and inter-observer reproducibility. K-
statistical evaluation revealed weak intra- and inter-observer
reproducibility of both grading systems (K<0.70). The K-
values were low, even when the Gleason scores were reduced
to three levels. Further analysis of intra-observer variability
for Gleason scores showed that the two observers differed by
only one point in 88% and 83% of the cases. For inter-
observer variation difference of only one Gleason point was
found in 74.5% of cases (average of two independent
gradings).
The results of the DNA ploidy distributions are given in
Table Ill. Overall 48% of tumours were diploid, 20% were
tetraploid and 32% were aneuploid. In the therapy-sensitive
group, 55% of the carcinomas were diploid, 15% were tetra-
ploid and 30% of the carcinomas were aneuploid. In the
therapy-resistant group of patients 41% of the carcinomas
were diploid, 25% were tetraploid and 34% were aneuploid.
There was no significant difference (P=0.38) between the
two outcome groups of patients with regard to diploid, tetra-
ploid and aneuploid tumours. Thus, DNA ploidy of the
primary prostate cancer could not discriminate between the
good- and bad-outcome groups of patients. There is, further-
more, no correlation between DNA ploidy and histological
grading (ploidy vs WHO, P= 0.80; ploidy vs Gleason,
P = 0.62).
Carcinoma of the prostate is a tumour with considerable
biological variability. Even after metastases appear, survival
varies considerably. Clinical stage and histological grade are
accepted as important parameters for therapy decision and
prediction of prognosis. There is a general agreement regard-
ing the prognostic value of histological grading systems for
carcinomas of the prostate gland, poorly differentiated car-
cinomas showing more aggressive behaviour than well-differ-
entiated tumours (Broders, 1926; Whitmore, 1973; Gleason et
al., 1974; Mostofi, 1976). As the treatment decision for any
individual prostatic cancer patient is influenced by histo-
logical grade, the accuracy as well as the reproducibility of
different grading systems are of utmost importance (ten Kate
et al., 1986).
The present study involved 59 patients chosen from the
273 patients in the SPCG-2 study (J0rgensen et al., 1993).
The SPCG-2 study was designed to include only well-differ-
entiated and moderately differentiated tumours. Two experi-
enced pathologists reviewed the histological slides from these
59 patients independently, and 27% and 37% of the tumours
were graded as poorly differentiated. The histologial slides
were also reviewed on two separate occasions. Finally, as a
final control the two pathologists reviewed them together. At
this consensus meeting, 56% of tumours were graded as
poorly differentiated. Thus a weak inter- as well as intra-
observer reproducibility was disclosed for both grading
systems (K <0.70). When the x-value for the traditional
Gleason system was calculated, even worse inter- and intra-
observer reproducibility was disclosed. The Gleason system is
the sum of the two most dominant growth patterns, each
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Table I Distribution of WHO and Gleason histological grades in the two outcome groups
of patients, after Gleason scores (2-10) were reducd to three levels
Histological grading distribution
WHO Gleason
Therapy Therapy Therapy Therapy
sensitive resistant sensitive resistant
Level 1 2 (8%) 5 (16%) 7 3 (11%) 6 (19%) 9
Level 2 9 (33%) 10 (31%) 19 20 (74%) 21 (66%) 41
Level 3 16 (59%) 17 (53%) 33 4 (15%) 5 (15%) 9
Total 27 (100%) 32 (100%) 59 27 (100%) 32 (100%) 59
Table H The overall agreement, one- or two-level disagreement, agreement by chance and K-values
after Gleason were reduced to three levels. 'A' and 'B' are the two pathologists' intra-observer results. I
and II are the inter-observer results after the two pathologists independently reviewed all the
histological slides on two different occasions
Intra-observer Inter-observer
WHO Gleason WHO Gleason
A B A B I II I II
Overall agreement 0.70 0.61 0.80 0.78 0.66 0.71 0.75 0.70
Disagree I level 0.30 0.37 0.18 0.20 0.34 0.25 0.25 0.25
Disagree >1 level 0.00 0.02 0.02 0.02 0.00 0.04 0.00 0.05
Agreement by chance 0.45 0.43 0.60 0.51 0.46 0.41 0.56 0.54
Kappa (K) 0.46 0.32 0.49 0.55 0.37 0.52 0.42 0.34
Table m DNA ploidy distributions in the two outcome groups of
patients
DNA ploidy distributions
Therapy sensitive Therapy resistant
Diploid 15 (55%) 13 (41%) 28
Tetraploid 4 (15%) 8 (25%) 12
Aneuploid 8 (30%) 11 (34%) 19
Total 27 (100%) 32 (100%) 59
scored from 1 to 5. The Gleason sum therefore ranges from 2
to 10, and intra- and inter-observer variation may easily
occur. Our results are in accordance with other reports
(Mostofi, 1976; ten Kate et al., 1986; Gleason, 1992; Swan-
holm et al., 1992) and stress that histological grading is
subjective and inaccurate. Thus, histological grade is not a
reliable factor when used as an inclusion/exclusion criterion
in clinical trials or as a parameter for treatment decision.
Bearing in mind the low reproducibility, the results of our
study indicate that histological grade is less important than
usually anticipated.
The present study was designed in such a way that the
clinical outcome differed significantly for the two groups of
patients. The first group consisted of patients who expenenc-
ed fast progression and death due to cancer despite endocrine
ablation treatment. The second group consisted of patients
who showed a good response to endocrine ablation treatment
and a favourable prognosis. If there is any prognostic impor-
tance of histological grade for the individual patient with
metastatic prostatic cancer, we should expect a high rate of
poorly differentiated tumours or high Gleason scores in the
poor-prognosis group. Likewise, those patients with well-
differentiated tumours and low Gleason scores should be in
the good-prognosis group. However, this was not the case.
According to the WHO classification, two of seven high-
grade tumours were from patients in the good-prognosis
group and the remaining five were from patients with a poor
prognosis. Of the 33 poorly differentiated tumours, 16 were
in the good-prognosis group compared with 17 in the poor-
prognosis group. With respect to the Gleason system, nine
patients had Gleason scores of 3 and 4, and of these three
patients belonged to the good-prognosis group and six
belonged to the poor-prognosis group. Nine patients had
tumours with a Gleason score of 8 or 9, which are expected
to be aggressive. Four of these belonged to the good-
prognosis group and five to the poor-prognosis group. We
were not able to find any prognostic value of the two com-
mon histological grading systems in patients with metastatic
prostatic cancer. Similar conclusions have been reached in
other studies in which several multivariate analyses of prog-
nostic factors in metastatic prostate cancer have disclosed
weak prognostic importance of histological grading (Emrich
et al., 1985; De Voogt et al., 1989; Mulders et al., 1990; Ernst
et al., 1991; Hedlund et al., 1991). On the other hand, a
similarly designed study (Miller et al., 1991) found that 76%
of poorly differentiated tumours occurred in a bad outcome
group and 65% of the well-differentiated tumours occurred
in a good-outcome group in patients with metastatic disease.
Because of the possibility of using paraffin-embedded
archival tumour material for DNA ploidy analysis, patient
groups with known clinical outcome can be selected for
studies of the prognostic value of ploidy. A review of 47
different DNA ploidy studies involving 3493 patients has
indicated that in most studies DNA aneuploidy is positively
correlated with high-grade tumours, advanced stage and,
consequently, with short time to progression and death
(Visakorpi et al., 1993). Most ofthese studies were performed
on localised or locally advanced-stage disease. Only a few
studies on metastatic (Ml) disease have been reported. The
present analysis of 59 cases did not demonstrate any
signifint difference (P = 0.38) between the two outcome
groups of patients with regard to diploid, tetraploid and
aneuploid tumours. Our results concur with other ploidy
investigations on metastatic prostatic cancer (White et al.,
1990; Adolfsson and Tribukait, 1991; Hedlund et al., 1991).
When distant metastases have appeared, the prognostic
importance of DNA ploidy seems to be low. Miller et al.
(1991) also found overall the same distribution of diploid,
tetraploid and aneuploid tumours as the present study. On
the other hand, Miller et al. found that 64% of diploid
tumours occurred in patients in a good-outcome group and
88% of non-diploid tumours in patients in a poor-outcome
group, compared with 54% and 62%, respectively, in our
study. Miller et al. concluded that DNA ploidy was a highly
significant prognostic factor. One explanation for these diver-
gent results may be that Miller et al. used stricter patient
selection criteria. The patients in the poor-outcome group
died during the first year, whereas those in the good-outcome
group survived for more than 5 years. In general, less than
20% of patients survive more than 5 years after distant
metastases have appeared (Blacard et al., 1973), a fact that
may explain the imbalance in the number of patients in theRopiostic makers in mxta
c p ostaic cancer
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two outcome groups in the study by Miller et al. (1991).
However, Miller et al found non-diploid tumours (36%) in
the good-prognosis group and diploid tumours (12%) in the
poor-prognosis group.
Some reports indicate that diploid and tetraploid tumours
respond better to hormonal therapy than aneuploid tumours
(Tavares et al., 1973; Zetteberg and Esposti, 1980; Zetteberg
and Forsslund, 1991). In these studies the endocrine treat-
ment was initiated at earlier stages of the disease, where
DNA ploidy has indicated important prognostic information
for groups of patients. The present study confirms other
reports (White et al., 1990; Adolfsson and Tribukait, 1991;
Hedlund et al., 1991) that ploidy cannot predict the response
to endocrine treatment in individual patients when distant
metastases have already appeared.
When analysing tumour material from the prostate gland,
heterogeneity within the tumour should be taken into
account (Lange and Narayan, 1983). Most of our biopsies
were obtained by TUR, only six by Tru-cut and two by open
prostatectomy. TUR mostly samples tissue from transitional
zone lobes and periuretheral glands (Villers et al., 1991), and
the tissue samples are dependent on how 'radical' is the
resection performed. Seventy per cent of the patients had
tumours of T category 3 or 4. These tumours may originate
from the peripheral zone, and the cancer tissue obtained by
TUR might be representative of the biological potential of
the cancer tissue that has invaded the prostate capsule or
periprostatic tissue. Even though there is no general consen-
sus regarding the histogram analysis, and the histological
material analysed might represent the most aggressive part of
the tumour, a similar percentage of aneuploid tumours
(Table III) was found in both patient groups.
To conclude, we could not find any significant differences
between therapy-sensitive and therapy-resistant patients when
using either histological grade or ploidy status evaluation.
When distant metastases have appeared the prognostic
importance of histological grade as well as DNA ploidy
seems to be minor according to present results. Furthermore,
histological grading is subjective and inaccurate. Future
investigations should search for other prognostic factors that
can predict more accurately the outcome in individual
patients with metastatic prostatic cancer.
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